AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27129607 — intervention group
Group type: COMPARATOR
Intervention: Home-Based Exercise (HBE)
Number of subjects: 152
Study 26913620 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent social‐cognitive intervention program (P‐SCIP)
Number of subjects: 218
Study 26913620 — intervention group
Group type: COMPARATOR
Intervention: Best-practice psychosocial care (BPC)
Number of subjects: 218
Study 25399658 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine treatment
Number of subjects: 9961
Study 23019380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning paradigm using clearly visible cues for high and low pain
Number of subjects: 40
Study 23019380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned placebo and nocebo responses triggered by nonconscious (masked) exposures to the same cues
Number of subjects: 40
Study 19200370 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 21
Study 17335405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with enamel matrix derivative (EMD)
Number of subjects: 14
Study 17335405 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) alone
Number of subjects: 14
Study 14697471 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction disorders (CDs) present during admission
Number of subjects: 0
Study 14697471 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete atrioventricular block
Number of subjects: 0
Study 14697471 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block
Number of subjects: 0
Study 14697471 — intervention group
Group type: COMPARATOR
Intervention: Patients without conduction disorders (CDs)
Number of subjects: 0
Study 11567913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0
Study 9543613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d. for 7 days starting 5 days before chemotherapy)
Number of subjects: 8
Study 7932825 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated drug delivery (schedule B)
Number of subjects: 92
Study 7932825 — intervention group
Group type: COMPARATOR
Intervention: Constant-rate drug delivery (schedule A)
Number of subjects: 92
Study 3284943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous APSAC (30 U in 2 to 4 min)
Number of subjects: 240
Study 3284943 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase (160,000 U over 60 min)
Number of subjects: 240
Study 3284943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous APSAC
Number of subjects: 240
Study 3284943 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 240
Study 29446098 — intervention group
Group type: EXPERIMENTAL
Intervention: VDZ-aTNF (Vedolizumab with anti-TNF co-exposure)
Number of subjects: 75
Study 29446098 — intervention group
Group type: COMPARATOR
Intervention: VDZ (Vedolizumab without anti-TNF co-exposure)
Number of subjects: 75
Study 29446098 — intervention group
Group type: EXPERIMENTAL
Intervention: VDZ-aTNF
Number of subjects: 75
Study 29446098 — intervention group
Group type: COMPARATOR
Intervention: VDZ
Number of subjects: 75
Study 29446098 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free remission
Number of subjects: 75
Study 29446098 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free response
Number of subjects: 75
Study 29446098 — intervention group
Group type: COMPARATOR
Intervention: VDZ-aTNF and VDZ
Number of subjects: 75
Study 29446098 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (separate cohort)
Number of subjects: 75
Study 27603509 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified modified Atkins diet
Number of subjects: 81
Study 27603509 — intervention group
Group type: COMPARATOR
Intervention: No dietary intervention (Control)
Number of subjects: 81
Study 24750013 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with cardiopulmonary bypass
Number of subjects: 60
Study 24750013 — intervention group
Group type: COMPARATOR
Intervention: Surgery without cardiopulmonary bypass
Number of subjects: 60
Study 24750013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 60
Study 22519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg.kg(‐1) followed by continuous infusion of 15 mg.kg(‐1).h(‐1))
Number of subjects: 40
Study 22519866 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 40
Study 22519866 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 40
Study 20497133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure ethanol (targeted breathalyzer = 0.040 g/dl)
Number of subjects: 48
Study 20497133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exposure ethanol (targeted breathalyzer = 0.100 g/dl)
Number of subjects: 48
Study 20497133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 48
Study 18375328 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 6 mL/h
Number of subjects: 17
Study 18375328 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural infusion of ropivacaine 0.2% at a rate of 9 mL/h
Number of subjects: 17
Study 18375328 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of the two dosing regimens (6 mL/h vs 9 mL/h)
Number of subjects: 17
Study 16161996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous application of compound 19 (BIBN4096)
Number of subjects: 0
Study 16161996 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP receptor antagonists (compound 19)
Number of subjects: 0
Study 12418600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (40%) application
Number of subjects: 40
Study 12418600 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 40
Study 10353516 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dapsone (2 mg/kg)
Number of subjects: 94
Study 10353516 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dapsone (1 mg/kg)
Number of subjects: 94
Study 10353516 — intervention group
Group type: COMPARATOR
Intervention: Weekly dapsone (4 mg/kg)
Number of subjects: 94
Study 10353516 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dapsone (1 mg/kg) and Daily dapsone (2 mg/kg)
Number of subjects: 94
Study 8600628 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc
Number of subjects: 12
Study 8600628 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 8440768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/day tirilazad mesylate
Number of subjects: 50
Study 8440768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/day tirilazad mesylate
Number of subjects: 50
Study 8440768 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg/day tirilazad mesylate
Number of subjects: 50
Study 8440768 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg/kg/day tirilazad mesylate
Number of subjects: 50
Study 8440768 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mg/kg/day tirilazad mesylate
Number of subjects: 50
Study 8440768 — intervention group
Group type: COMPARATOR
Intervention: Citrate vehicle placebo
Number of subjects: 50
Study 8440768 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline placebo
Number of subjects: 50
Study 3092653 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms)
Number of subjects: 0
Study 3092653 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (dose not specified)
Number of subjects: 0
Study 29927930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 3879
Study 29927930 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3879
Study 27714459 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis + Sodium hyaluronate (SH) injection
Number of subjects: 30
Study 27714459 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis only
Number of subjects: 30
Study 25635327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 25635327 — intervention group
Group type: COMPARATOR
Intervention: Platelet activation
Number of subjects: 0
Study 22729967 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA supplementation (8 g of pure DPA)
Number of subjects: 10
Study 22729967 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA supplementation (8 g of pure EPA)
Number of subjects: 10
Study 22729967 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (olive oil)
Number of subjects: 10
Study 21708185 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum 20 minutes of daily commuter cycling during 8 weeks
Number of subjects: 48
Study 21708185 — intervention group
Group type: COMPARATOR
Intervention: No change in lifestyle (control group)
Number of subjects: 48
Study 17869446 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (FU) plus leucovorin (LV) (FU+LV)
Number of subjects: 155
Study 17869446 — intervention group
Group type: EXPERIMENTAL
Intervention: oral uracil and tegafur (UFT) plus LV (UFT+LV)
Number of subjects: 155
Study 16424784 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 250
Study 16424784 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 250
Study 14521531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg per day for 10 days)
Number of subjects: 182
Study 14521531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (750 mg glucose per day for 10 days)
Number of subjects: 182
Study 14521531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 182
Study 14521531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 10856481 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46
Study 10856481 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46
Study 10856481 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU subcutaneous (s.c.) recombinant FSH
Number of subjects: 46
Study 10856481 — intervention group
Group type: COMPARATOR
Intervention: 150 IU intramuscular (i.m.) recombinant FSH
Number of subjects: 46
Study 7733035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molybdenum diet (22 micrograms/d) for 102 days
Number of subjects: 4
Study 7733035 — intervention group
Group type: EXPERIMENTAL
Intervention: Molybdenum-supplemented diet (467 micrograms/d) for 18 days
Number of subjects: 4
Study 7733035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary molybdenum intake
Number of subjects: 4
Study 7733035 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary molybdenum intake
Number of subjects: 4
Study 7733035 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of minimum dietary molybdenum requirement
Number of subjects: 4
Study 2103967 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cyclodextrin-piroxicam (beta CDP)
Number of subjects: 40
Study 2103967 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone (NAB)
Number of subjects: 40
Study 7339229 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days per week training
Number of subjects: 75
Study 7339229 — intervention group
Group type: COMPARATOR
Intervention: 4 days per week training
Number of subjects: 75
Study 7339229 — intervention group
Group type: COMPARATOR
Intervention: 3 days per week training
Number of subjects: 75
Study 7339229 — intervention group
Group type: COMPARATOR
Intervention: 2 days per week training
Number of subjects: 75
Study 7339229 — intervention group
Group type: COMPARATOR
Intervention: 1 day per week training
Number of subjects: 75
Study 30913217 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA) with detailed information on benefits and harms of screening
Number of subjects: 400
Study 30913217 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflet that did not mention harms
Number of subjects: 400
Study 30913217 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA)
Number of subjects: 400
Study 30913217 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflet
Number of subjects: 400
Study 28124534 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation with pelvic floor muscle training (ES + PFMT)
Number of subjects: 60
Study 28124534 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 60
Study 25231677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1,200 mg/day
Number of subjects: 323
Study 25231677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 23652739 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst multibracket (MB) treatment
Number of subjects: 37
Study 21612746 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg)
Number of subjects: 24
Study 21612746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21612746 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (25 mg) with Roflumilast
Number of subjects: 24
Study 21612746 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg) with Placebo
Number of subjects: 24
Study 19127171 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-OROS
Number of subjects: 19
Study 19127171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16433771 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day)
Number of subjects: 213
Study 16433771 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (1-3 mg/kg/day)
Number of subjects: 213
Study 15541209 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 20-mg tablets, administered twice daily
Number of subjects: 0
Study 15541209 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily
Number of subjects: 0
Study 11775562 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ml (5700 IU) of nadroparin
Number of subjects: 60
Study 11775562 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml (9500 IU) of nadroparin
Number of subjects: 60
Study 9280815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (reviparin sodium)
Number of subjects: 1021
Study 9280815 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (adjusted-dose, intravenous)
Number of subjects: 1021
Study 7839476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nebulized budesonide
Number of subjects: 37
Study 7839476 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 37
Study 3222154 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic Irradiation (SI)
Number of subjects: 660
Study 3222154 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 660
Study 3222154 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil with or without prednisolone
Number of subjects: 660
Study 3222154 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic Irradiation (SI) vs Chlorambucil with or without prednisolone
Number of subjects: 660
Study 31698359 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous AT (SAT) mass, Visceral AT (VAT) mass, and gene expression in SAT
Number of subjects: 156
Study 31698359 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous AT (SAT) mass
Number of subjects: 156
Study 28275830 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 180
Study 28275830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 180
Study 28275830 — intervention group
Group type: COMPARATOR
Intervention: Varenicline vs. Bupropion
Number of subjects: 180
Study 25401522 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 41
Study 25401522 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 41
Study 25401522 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 23631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 418
Study 23631869 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 418
Study 23631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Assistance Income
Number of subjects: 418
Study 23631869 — intervention group
Group type: EXPERIMENTAL
Intervention: Illegal Income
Number of subjects: 418
Study 21399454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves (positive-displacement valves)
Number of subjects: 0
Study 21399454 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-septum devices
Number of subjects: 0
Study 21399454 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-, negative-, and positive-displacement types
Number of subjects: 0
Study 18484151 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen implant
Number of subjects: 20
Study 18484151 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 20
Study 16980862 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal maxillary distractors
Number of subjects: 29
Study 16980862 — intervention group
Group type: COMPARATOR
Intervention: Immediate fragment transposition using miniplates and screw fixation (Control)
Number of subjects: 29
Study 14523272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine triphosphate above 30 fmol/10(6) cells
Number of subjects: 33
Study 14523272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine triphosphate above 7017 fmol/10(6) cells
Number of subjects: 33
Study 14523272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine triphosphate concentrations
Number of subjects: 33
Study 14523272 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphosphate concentrations in women
Number of subjects: 33
Study 14523272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-RNA level under 50 copies/ml
Number of subjects: 33
Study 14523272 — intervention group
Group type: COMPARATOR
Intervention: Indinavir concentrations
Number of subjects: 33
Study 10801756 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (9 g daily for 1 month)
Number of subjects: 30
Study 10801756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8739380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the penis using an electromechanical hammer with surface electrodes.
Number of subjects: 21
Study 8739380 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the penis.
Number of subjects: 21
Study 1425206 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine (60 mg t.i.d. for 7 days)
Number of subjects: 20
Study 1425206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 20
Study 1425206 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine and Placebo
Number of subjects: 20
Study 4017833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (40 micrograms/kg/4 hr)
Number of subjects: 6
Study 4017833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerulein (360 ng/kg/4 hr)
Number of subjects: 6
Study 4017833 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 29891566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms in mothers (Patient Health Questionnaire‐9 ≥5)
Number of subjects: 1031
Study 29891566 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to physical IPV
Number of subjects: 1031
Study 29891566 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexual IPV
Number of subjects: 1031
Study 26948850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher third-trimester stress
Number of subjects: 136
Study 26948850 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned cesarean delivery
Number of subjects: 136
Study 26948850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 136
Study 26948850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic covariates, mode of delivery, and prenatal mood
Number of subjects: 136
Study 24241212 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib at a maximum tolerated dose of 0.25 mg/kg
Number of subjects: 24
Study 24241212 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 23256712 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for general practitioners and pediatricians
Number of subjects: 30000
Study 23256712 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training plus point-of-care testing
Number of subjects: 30000
Study 23256712 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30000
Study 21067470 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg dexamethasone cipecilate
Number of subjects: 28
Study 21067470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17426473 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 3 months preoperatively (Group III)
Number of subjects: 0
Study 17426473 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for unspecified duration (Group I)
Number of subjects: 0
Study 17426473 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for unspecified duration (Group II)
Number of subjects: 0
Study 17426473 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 0
Study 15739076 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg, single dose)
Number of subjects: 92
Study 15739076 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg/day for 6 weeks)
Number of subjects: 92
Study 12073414 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder (753 patients)
Number of subjects: 2626
Study 12073414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminder (phone call, 312 patients)
Number of subjects: 2626
Study 12073414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminder (letter, 337 patients)
Number of subjects: 2626